Ursodeoxycholic Acid Market is expected to reach US$ 1120.55 million by 2031 | Glenmark Pharmaceuticals Inc., Biobrick Pharma, Casca Remedies Pvt. Ltd., Wellona Pharma

Ursodeoxycholic Acid Market reached US$ 581.17 million in 2023 and is expected to reach US$ 1120.55 million by 2031 growing with a CAGR of 9.8% during the forecast period 2024-2031.

The Ursodeoxycholic Acid Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.

Download your exclusive sample report today: (corporate email gets priority access): https://datamintelligence.com/download-sample/ursodeoxycholic-acid-market?sg

Ursodeoxycholic Acid Market Landscape Analysis :

Ursodeoxycholic acid (UDCA) is a bile acid widely used as an Active Pharmaceutical Ingredient (API) in the treatment of cholestatic liver diseases and gallbladder conditions. It can be derived from natural sources or produced synthetically in laboratory settings.

The primary mechanism of UDCA involves altering the composition of bile-a fluid produced by the liver to aid digestion. By reducing the cholesterol concentration within bile, UDCA lowers its cholesterol saturation, which in turn helps prevent the formation of gallstones. This property makes UDCA especially valuable in dissolving cholesterol-based gallstones, offering a non-invasive alternative for patients who may not be suitable candidates for surgery due to age, underlying health issues, or other medical risks.

UDCA's effectiveness in managing bile composition and improving liver function underscores its importance in therapeutic strategies for hepatobiliary conditions.

Ursodeoxycholic Acid Market: Shifting Industry Trends and Market Potential

Rising Prevalence of Liver Diseases Fueling Demand for Ursodeoxycholic Acid (UDCA)

The global market for ursodeoxycholic acid (UDCA) is witnessing steady growth, largely driven by the increasing incidence of liver diseases. Conditions such as Primary Biliary Cholangitis (PBC) and Non-Alcoholic Fatty Liver Disease (NAFLD) are becoming more widespread due to shifting lifestyle habits, rising obesity rates, and an aging global population. These trends are contributing to a growing need for effective treatments like UDCA.

According to a February 2023 study published by the National Center for Biotechnology Information (NCBI), NAFLD is now among the most common liver disorders worldwide. The estimated global incidence is around 47 cases per 1,000 people, with men being more frequently affected than women. The study also reports a global adult prevalence rate of 32%, with approximately 40% of men and 26% of women impacted by the condition.

In addition to rising disease prevalence, ongoing product innovation and supportive government initiatives in research and development are boosting market momentum. For example, Biofield Pharma Pvt Ltd recently introduced a new product, URSOGET, which contains 300 mg of ursodeoxycholic acid per tablet. The product is distributed in ALU-ALU blister packs, with each pack containing 10 tablets in a 10x10 format.

With growing clinical research, product launches, and heightened awareness about liver health, the UDCA market is expected to expand significantly in the coming years.

Strategic Players Driving the Ursodeoxycholic Acid Market Forward: Glenmark Pharmaceuticals Inc., Biobrick Pharma, Casca Remedies Pvt. Ltd., Wellona Pharma, ADDII BIOTECH PRIVATE LIMITED., Curivo Healthcare, Zoic Life Sciences, Biofield Pharma Pvt Ltd, Jabs Biotech Pvt. Ltd, and Captee.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/ursodeoxycholic-acid-market?sg

Research Methodology:

The global Ursodeoxycholic Acid Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Ursodeoxycholic Acid Market:

By Type (Synthetic Ursodeoxycholic Acid (UDCA), Biological Ursodeoxycholic Acid (UDCA))

By Application (Gallstones, Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), Other Liver and Biliary Diseases)

By Form (Tablets, Capsules, Suspension)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Recent Development

In August 2024, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC). This approval allows Livdelzi to be used in combination with ursodeoxycholic acid (UDCA) for adults who have not responded adequately to UDCA and as a monotherapy for patients who are unable to tolerate UDCA.

Regional Analysis for Ursodeoxycholic Acid Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Most Frequently Asked Questions in the Ursodeoxycholic Acid Market Research Industry:

➠ Who leads the Ursodeoxycholic Acid industry and what's their competitive positioning regarding capacity, performance, and profitability?

➠ What growth opportunities and market challenges do Ursodeoxycholic Acid market vendors face?

➠ Which segments show the highest growth potential and market share distribution?

➠ What factors are driving or limiting Ursodeoxycholic Acid market growth?

➠ What are the dominant sales and distribution strategies in the Ursodeoxycholic Acid industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.